CN107531764A - 结核分枝杆菌抗原及其应用 - Google Patents

结核分枝杆菌抗原及其应用 Download PDF

Info

Publication number
CN107531764A
CN107531764A CN201580079653.6A CN201580079653A CN107531764A CN 107531764 A CN107531764 A CN 107531764A CN 201580079653 A CN201580079653 A CN 201580079653A CN 107531764 A CN107531764 A CN 107531764A
Authority
CN
China
Prior art keywords
tuberculosis
nucleic acid
seq
mycobacterium
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580079653.6A
Other languages
English (en)
Inventor
刘军
张鹭
郭沛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Yongan Pharmaceutical Co ltd
Jinjiang Hengyuan Technology Development Co ltd
Fudan University
Original Assignee
Chengdu Yongan Pharmaceutical Co ltd
Jinjiang Hengyuan Technology Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Yongan Pharmaceutical Co ltd, Jinjiang Hengyuan Technology Development Co ltd filed Critical Chengdu Yongan Pharmaceutical Co ltd
Publication of CN107531764A publication Critical patent/CN107531764A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了一种包含结核分枝杆菌抗原Rv0976c，Rv1255c，Rv3160c和/或Rv0792c或其编码基因的免疫原性组合物、疫苗或治疗性组合物。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201580079653.6A 2015-06-15 2015-09-29 结核分枝杆菌抗原及其应用 Pending CN107531764A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510324548.6A CN106237317A (zh) 2015-06-15 2015-06-15 由结核分枝杆菌抗原组成的结核疫苗
CN2015103245486 2015-06-15
PCT/CN2015/091068 WO2016201825A1 (zh) 2015-06-15 2015-09-29 结核分枝杆菌抗原及其应用

Publications (1)

Publication Number Publication Date
CN107531764A true CN107531764A (zh) 2018-01-02

Family

ID=57546635

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510324548.6A Pending CN106237317A (zh) 2015-06-15 2015-06-15 由结核分枝杆菌抗原组成的结核疫苗
CN201580079653.6A Pending CN107531764A (zh) 2015-06-15 2015-09-29 结核分枝杆菌抗原及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510324548.6A Pending CN106237317A (zh) 2015-06-15 2015-06-15 由结核分枝杆菌抗原组成的结核疫苗

Country Status (2)

Country Link
CN (2) CN106237317A (zh)
WO (1) WO2016201825A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7035063B2 (ja) * 2017-04-07 2022-03-14 ジュン・リウ ｐｈｏＰ－ｐｈｏＲを過剰発現する組換えＢＣＧ
WO2019147509A1 (en) * 2018-01-26 2019-08-01 The Regents Of The University Of California Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN114272364B (zh) * 2021-12-22 2024-06-18 中国人民解放军总医院第八医学中心 一种结核分枝杆菌串联dna疫苗w541及其制备方法与应用
CN116041541B (zh) * 2022-11-30 2024-03-15 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原eppa011及其应用
CN116003540B (zh) * 2022-12-08 2024-04-16 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原组合物pfhp010的制备及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1342771A (zh) * 2001-09-17 2002-04-03 复旦大学 结核分枝杆菌Ag85B抗原的表达纯化和作为疫苗组份的应用
US20110117133A1 (en) * 2007-11-27 2011-05-19 Avigdor Shafferman Novel Recombinant BCG Tuberculosis Vaccine Designed to Elicit Immune Responses to Mycobacterium Tuberculosis in all Physiological Stages of Infection and Disease
CN102161695A (zh) * 2011-03-08 2011-08-24 复旦大学 一种用于耐药结核血清学诊断的Rv1793重组蛋白
CN102260328A (zh) * 2010-07-15 2011-11-30 华中农业大学 结核分枝杆菌的抗原蛋白及应用
CN102666575A (zh) * 2009-10-16 2012-09-12 艾西斯创新有限公司 分枝杆菌疫苗
CN103304646A (zh) * 2012-03-09 2013-09-18 中国医学科学院病原生物学研究所 结核分枝杆菌候选抗原多肽及其应用
US20140004151A1 (en) * 2011-09-30 2014-01-02 La Jolla Institute For Allergy And Immunology Antigens and Epitopes Derived From Mycobacterium Tuberculosis
CN104292315A (zh) * 2014-10-27 2015-01-21 武汉大学 一种Rv2645蛋白的制备及其在结核诊断与重组BCG疫苗中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504523A (ja) * 2001-06-22 2005-02-17 ヘルス プロテクション エージェンシー 低酸素圧下で発現するマイコバクテリア抗原
ITRM20030411A1 (it) * 2003-08-29 2005-02-28 Consiglio Nazionale Ricerche Uso di sequenze geniche specifiche di mycobacterium tubercolosis ecorrispondenti proteine per la diagnosi e la prevenzione di infezione tubercolare.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1342771A (zh) * 2001-09-17 2002-04-03 复旦大学 结核分枝杆菌Ag85B抗原的表达纯化和作为疫苗组份的应用
US20110117133A1 (en) * 2007-11-27 2011-05-19 Avigdor Shafferman Novel Recombinant BCG Tuberculosis Vaccine Designed to Elicit Immune Responses to Mycobacterium Tuberculosis in all Physiological Stages of Infection and Disease
CN102666575A (zh) * 2009-10-16 2012-09-12 艾西斯创新有限公司 分枝杆菌疫苗
CN102260328A (zh) * 2010-07-15 2011-11-30 华中农业大学 结核分枝杆菌的抗原蛋白及应用
CN102161695A (zh) * 2011-03-08 2011-08-24 复旦大学 一种用于耐药结核血清学诊断的Rv1793重组蛋白
US20140004151A1 (en) * 2011-09-30 2014-01-02 La Jolla Institute For Allergy And Immunology Antigens and Epitopes Derived From Mycobacterium Tuberculosis
CN103304646A (zh) * 2012-03-09 2013-09-18 中国医学科学院病原生物学研究所 结核分枝杆菌候选抗原多肽及其应用
CN104292315A (zh) * 2014-10-27 2015-01-21 武汉大学 一种Rv2645蛋白的制备及其在结核诊断与重组BCG疫苗中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENBANK: "MULTISPECIES: hypothetical protein [Mycobacterium tuberculosis complex]，NCBI Reference Sequence: WP_003404960.1", 《GENBANK》 *
沈洪波等: "结核病疫苗研究进展", 《生命的化学》 *

Also Published As

Publication number Publication date
CN106237317A (zh) 2016-12-21
WO2016201825A1 (zh) 2016-12-22

Similar Documents

Publication Publication Date Title
CN107531764A (zh) 结核分枝杆菌抗原及其应用
Tanghe et al. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer
Brodin et al. ESAT-6 proteins: protective antigens and virulence factors?
Delogu et al. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis
CN102836425B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
US8173773B2 (en) Mycobacterium tuberculosis fusion protein and uses thereof
Xu et al. Constitutive expression of outer surface protein C diminishes the ability of Borrelia burgdorferi to evade specific humoral immunity
Sereinig et al. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge
CN102573896A (zh) 结核分枝杆菌免疫优势抗原的组合物和方法
CN110506108B (zh) 过表达phoP-phoR的重组BCG
Zhang et al. Effect of vaccination on Bordetella pertussis strains, China
Teimourpour et al. Construction of a DNA vaccine encoding Mtb32C and HBHA genes of Mycobacterium tuberculosis
WO2001079274A2 (en) Tuberculosis antigens and methods of use thereof
Vordermeier et al. Toward the development of diagnostic assays to discriminate between Mycobacterium bovis infection and bacille Calmette-Guerin vaccination in cattle
CN102439134B (zh) 包含过表达PhoP和/或PhoP调节子蛋白的重组BCG菌株的结核疫苗
Haynes et al. Evaluation of the protective ability of the Treponema pallidum subsp. pallidum Tp0126 OmpW homolog in the rabbit model of syphilis
Fan et al. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model
Roupie et al. Immunogenicity and protective efficacy of DNA vaccines encoding MAP0586c and MAP4308c of Mycobacterium avium subsp. paratuberculosis secretome
Wang et al. Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis
Mulongo et al. Cattle immunized against the pathogenic L-α-glycerol-3-phosphate oxidase of Mycoplasma mycoides subs. mycoides fail to generate neutralizing antibodies and succumb to disease on challenge
Xiang et al. Immunogenicity and protective efficacy of a fusion protein tuberculosis vaccine combining five Esx family proteins
Rashidian et al. Designing and construction of a DNA vaccine encoding tb10. 4 gene of Mycobacterium tuberculosis
CN105567660A (zh) 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
CN107530414B (zh) 区分活动性结核病和潜伏结核感染的结核分枝杆菌抗原及其应用
Mon et al. Evaluation of cocktails with recombinant proteins of Mycobacterium bovis for a specific diagnosis of bovine tuberculosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102